US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

DOGWOOD THERAPEUTICS INC

2.49

+0.16006.87%

Post-market: 2.490.00000.00%19:30 EDT

Volume:123.60K

Turnover:301.16K

Market Cap:84.64M

PE:-1.45

High:2.58

Open:2.31

Low:2.31

Close:2.33

52wk High:9.50

52wk Low:1.28

Shares:33.99M

Float Shares:5.81M

Volume Ratio:1.80

T/O Rate:2.13%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.7149

EPS(LYR):-7.1350

ROE:-47.77%

ROA:-20.83%

PB:1.24

PE(LYR):-0.35

Loading ...

Overview Company News Filings

Dogwood Therapeutics to Host Virtual KOL Event on Halneuron for Chemotherapy-Induced Neuropathic Pain

Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)

Dogwood Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Dogwood Therapeutics Q2 FY26 Net Loss Widens to $11.5 Million

Dogwood Therapeutics Q2 EPS USD -0.34

THOMSON REUTERS

Press Release: Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

Dogwood Therapeutics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview

Dogwood Therapeutics Posts Corporate Presentation on Non-Opioid Pain, Neuropathy Drug Pipeline

Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial

MT Newswires Live

Dogwood enrolls first 200 patients in HAL-CINP trial

Dogwood Therapeutics Announces Press Release Availability

Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2B Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026

THOMSON REUTERS

Analysts Offer Insights on Healthcare Companies: Celcuity (CELC), Dogwood Therapeutics (DWTX) and Sanofi (OtherSNYNF)

Dogwood Therapeutics Posts Corporate Presentation on Non-opioid Pain, Neuropathy Drug Pipeline

Dogwood Therapeutics Names Orbimed’s Iain Dukes Chair of New Scientific Advisory Board

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at Orbimed, as Chair of Scientific Advisory Board

THOMSON REUTERS

Dogwood Therapeutics shareholders approve charter amendment increasing authorized shares

Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)

Dogwood Therapeutics launches 12-week Halneuron Phase 2b CINP extension trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/DWTX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"DWTX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","market":"US","secType":"STK","nameCN":"DOGWOOD THERAPEUTICS INC","latestPrice":2.49,"timestamp":1787342400000,"preClose":2.33,"halted":0,"volume":123599,"hourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.49,"latestTime":"19:30 EDT","volume":233,"amount":579.322,"timestamp":1787355006618,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.06866952789699576,"floatShares":5809900,"shares":33992600,"eps":-1.714933,"marketStatus":"Market Closed","change":0.16,"latestTime":"08-21 16:00:00 EDT","open":2.31,"high":2.5757,"low":2.31,"amount":301162.4728707,"amplitude":0.114034,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.714933,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"listingDate":1608181200000,"exchange":"NASDAQ","adjPreClose":2.33,"preHourTrading":{"tag":"盘前","latestPrice":2.35,"preClose":2.33,"latestTime":"08:57 EDT","volume":437,"amount":1029.8918840000001,"timestamp":1787317047077,"change":0.02,"changeRate":0.008584,"amplitude":0.047425},"postHourTrading":{"tag":"盘后","latestPrice":2.49,"preClose":2.49,"latestTime":"19:30 EDT","volume":233,"amount":579.322,"timestamp":1787355006618,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.8042912127710773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"DWTX\",,,,,undefined,":{"symbol":"DWTX","floatShares":5809900,"roa":"-20.83%","roe":"-47.77%","lyrEps":-7.13499,"volumeRatio":1.8042912127710773,"shares":33992600,"dividePrice":0,"high":2.5757,"amplitude":0.114034,"preClose":2.33,"low":2.31,"week52Low":1.28,"pbRate":"1.24","week52High":9.5,"institutionHeld":0,"latestPrice":2.49,"eps":-1.714933,"divideRate":0,"volume":123599,"delay":0,"ttmEps":-1.714933,"open":2.31,"prevYearClose":4.16,"prevWeekClose":2.15,"prevMonthClose":1.64,"prevQuarterClose":1.61,"fiveDayClose":2.15,"twentyDayClose":1.5,"sixtyDayClose":1.71},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DWTX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"DWTX","fiscalQuarterEnding":"2026/06","expectedEps":-0.13,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-0.34},{"market":"US","date":"2026-05-14","symbol":"DWTX","fiscalQuarterEnding":"2026/03","expectedEps":-0.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778731200000,"reportTimeType":"pre","actualEps":-0.15},{"market":"US","date":"2026-03-18","symbol":"DWTX","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773806400000,"reportTimeType":"pre","actualEps":-0.26},{"market":"US","date":"2025-11-06","symbol":"DWTX","fiscalQuarterEnding":"2025/09","expectedEps":-1.23,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-8.2},{"market":"US","date":"2025-08-13","symbol":"DWTX","fiscalQuarterEnding":"2025/06","expectedEps":-1.26,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-1.99}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DWTX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"DWTX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1745467200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/DWTX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"DWTX","date":"2026-08-21","current":-1.451952,"percent":0.189655,"low":-5.30677,"twenty":-2.17317,"median":-0.936241,"eighty":-0.421462,"high":-0.31572,"avg":-1.309805,"sd":1.001114,"marketCap":79202648},"quantilePoints":[{"date":"2024-10-11","current":-0.88829,"twenty":-0.871777,"median":-0.847007,"eighty":-0.822237,"marketCap":4156676},{"date":"2024-10-18","current":-1.14168,"twenty":-1.243599,"median":-1.14168,"eighty":-0.919038,"marketCap":5342394},{"date":"2024-10-25","current":-1.352393,"twenty":-1.244175,"median":-1.155915,"eighty":-1.05342,"marketCap":6328406},{"date":"2024-10-31","current":-1.184386,"twenty":-1.27834,"median":-1.174407,"eighty":-1.098974,"marketCap":5542234},{"date":"2024-11-08","current":-1.035557,"twenty":-1.27834,"median":-1.184386,"eighty":-1.098974,"marketCap":5928592},{"date":"2024-11-15","current":-0.74467,"twenty":-1.269799,"median":-1.17156,"eighty":-0.88829,"marketCap":4263257},{"date":"2024-11-22","current":-0.6306,"twenty":-1.266952,"median":-1.124597,"eighty":-0.74467,"marketCap":3610202},{"date":"2024-11-29","current":-0.558465,"twenty":-1.264674,"median":-1.042032,"eighty":-0.629204,"marketCap":3197227},{"date":"2024-12-06","current":-0.532869,"twenty":-1.261826,"median":-0.94447,"eighty":-0.591959,"marketCap":3050687},{"date":"2024-12-13","current":-0.560792,"twenty":-1.247591,"median":-0.805175,"eighty":-0.586099,"marketCap":3210548},{"date":"2024-12-20","current":-0.53985,"twenty":-1.196344,"median":-0.717909,"eighty":-0.564981,"marketCap":3090652},{"date":"2024-12-27","current":-0.609658,"twenty":-1.179261,"median":-0.679489,"eighty":-0.564515,"marketCap":3490306},{"date":"2025-01-03","current":-0.584061,"twenty":-1.174695,"median":-0.665504,"eighty":-0.565461,"marketCap":3343766},{"date":"2025-01-10","current":-0.553811,"twenty":-1.172405,"median":-0.646888,"eighty":-0.565454,"marketCap":3170583},{"date":"2025-01-17","current":-0.449099,"twenty":-1.164457,"median":-0.623619,"eighty":-0.558465,"marketCap":2571103},{"date":"2025-01-24","current":-3.106463,"twenty":-1.170151,"median":-0.6306,"eighty":-0.558465,"marketCap":17784576},{"date":"2025-01-31","current":-2.969173,"twenty":-1.244175,"median":-0.653869,"eighty":-0.558465,"marketCap":16998591},{"date":"2025-02-07","current":-2.748114,"twenty":-1.269799,"median":-0.667831,"eighty":-0.560792,"marketCap":15733022},{"date":"2025-02-14","current":-1.561376,"twenty":-1.386529,"median":-0.691147,"eighty":-0.563119,"marketCap":8938914},{"date":"2025-02-21","current":-1.36824,"twenty":-1.406654,"median":-0.738827,"eighty":-0.564981,"marketCap":7833206},{"date":"2025-02-28","current":-1.095988,"twenty":-1.389852,"median":-0.805175,"eighty":-0.565476,"marketCap":6274558},{"date":"2025-03-07","current":-1.030834,"twenty":-1.384928,"median":-0.926984,"eighty":-0.569177,"marketCap":5901548},{"date":"2025-03-14","current":-1.798723,"twenty":-1.448286,"median":-1.000651,"eighty":-0.577546,"marketCap":10297735},{"date":"2025-03-21","current":-1.056947,"twenty":-1.431015,"median":-0.999453,"eighty":-0.58313,"marketCap":13053004},{"date":"2025-03-28","current":-0.925409,"twenty":-1.421838,"median":-0.979572,"eighty":-0.584992,"marketCap":11428545},{"date":"2025-04-04","current":-0.646858,"twenty":-1.406654,"median":-0.930825,"eighty":-0.586099,"marketCap":7988515},{"date":"2025-04-11","current":-0.317141,"twenty":-1.389852,"median":-0.88829,"eighty":-0.58313,"marketCap":3916603},{"date":"2025-04-17","current":-0.402359,"twenty":-1.385328,"median":-0.805724,"eighty":-0.565469,"marketCap":4969023},{"date":"2025-04-25","current":-0.61055,"twenty":-1.374755,"median":-0.785584,"eighty":-0.565469,"marketCap":7540127},{"date":"2025-05-02","current":-0.578189,"twenty":-1.358732,"median":-0.74467,"eighty":-0.568254,"marketCap":7140474},{"date":"2025-05-09","current":-0.374989,"twenty":-1.330168,"median":-0.724741,"eighty":-0.565469,"marketCap":8714743},{"date":"2025-05-16","current":-0.451467,"twenty":-1.293145,"median":-0.691147,"eighty":-0.558465,"marketCap":10492092},{"date":"2025-05-23","current":-0.435842,"twenty":-1.273215,"median":-0.667831,"eighty":-0.549157,"marketCap":10128978},{"date":"2025-05-30","current":-0.43502,"twenty":-1.26866,"median":-0.661674,"eighty":-0.542709,"marketCap":10109867},{"date":"2025-06-06","current":-0.424679,"twenty":-1.265813,"median":-0.656935,"eighty":-0.524492,"marketCap":9335860},{"date":"2025-06-13","current":-0.450325,"twenty":-1.262965,"median":-0.649201,"eighty":-0.469065,"marketCap":9899643},{"date":"2025-06-20","current":-0.417289,"twenty":-1.258453,"median":-0.635392,"eighty":-0.460532,"marketCap":9173414},{"date":"2025-06-27","current":-0.414681,"twenty":-1.246626,"median":-0.62674,"eighty":-0.450325,"marketCap":9116080},{"date":"2025-07-03","current":-0.417289,"twenty":-1.244175,"median":-0.623619,"eighty":-0.448744,"marketCap":9173414},{"date":"2025-07-11","current":-0.433807,"twenty":-1.191392,"median":-0.616057,"eighty":-0.435137,"marketCap":9536528},{"date":"2025-07-18","current":-0.413812,"twenty":-1.184386,"median":-0.61055,"eighty":-0.430908,"marketCap":9096969},{"date":"2025-07-25","current":-0.411204,"twenty":-1.175845,"median":-0.606188,"eighty":-0.428591,"marketCap":9039635},{"date":"2025-08-01","current":-0.420332,"twenty":-1.175104,"median":-0.602999,"eighty":-0.424679,"marketCap":9240303},{"date":"2025-08-08","current":-0.425287,"twenty":-1.172969,"median":-0.594948,"eighty":-0.422505,"marketCap":9349238},{"date":"2025-08-15","current":-0.380049,"twenty":-1.170151,"median":-0.588976,"eighty":-0.421636,"marketCap":9402749},{"date":"2025-08-22","current":-0.381594,"twenty":-1.165796,"median":-0.584643,"eighty":-0.419028,"marketCap":9440972},{"date":"2025-08-29","current":-0.370394,"twenty":-1.14168,"median":-0.579408,"eighty":-0.417298,"marketCap":9163858},{"date":"2025-09-05","current":-0.386229,"twenty":-1.128014,"median":-0.578189,"eighty":-0.417289,"marketCap":9555640},{"date":"2025-09-12","current":-0.378257,"twenty":-1.116602,"median":-0.565465,"eighty":-0.414688,"marketCap":9358411},{"date":"2025-09-19","current":-0.371892,"twenty":-1.1021,"median":-0.560792,"eighty":-0.413812,"marketCap":9200934},{"date":"2025-09-26","current":-0.394726,"twenty":-1.096585,"median":-0.556138,"eighty":-0.410856,"marketCap":9765864},{"date":"2025-10-03","current":-0.495918,"twenty":-1.064755,"median":-0.553811,"eighty":-0.413012,"marketCap":12269441},{"date":"2025-10-10","current":-0.519049,"twenty":-1.045015,"median":-0.552647,"eighty":-0.413742,"marketCap":12841707},{"date":"2025-10-17","current":-0.55705,"twenty":-1.036852,"median":-0.55705,"eighty":-0.413812,"marketCap":13781903},{"date":"2025-10-24","current":-0.520902,"twenty":-1.035502,"median":-0.552647,"eighty":-0.413812,"marketCap":12887570},{"date":"2025-10-31","current":-0.61637,"twenty":-1.031765,"median":-0.55705,"eighty":-0.414507,"marketCap":15249527},{"date":"2025-11-07","current":-0.481974,"twenty":-1.007156,"median":-0.555431,"eighty":-0.414681,"marketCap":11924442},{"date":"2025-11-14","current":-0.327725,"twenty":-1.000768,"median":-0.549157,"eighty":-0.413742,"marketCap":12520664},{"date":"2025-11-21","current":-0.357136,"twenty":-0.998735,"median":-0.545565,"eighty":-0.409242,"marketCap":13644313},{"date":"2025-11-28","current":-0.391355,"twenty":-0.987046,"median":-0.544503,"eighty":-0.403493,"marketCap":14951645},{"date":"2025-12-05","current":-0.368541,"twenty":-0.971236,"median":-0.53985,"eighty":-0.398837,"marketCap":14080014},{"date":"2025-12-12","current":-4.995522,"twenty":-0.987046,"median":-0.53985,"eighty":-0.39658,"marketCap":190852899},{"date":"2025-12-19","current":-4.746524,"twenty":-1.032696,"median":-0.544503,"eighty":-0.398429,"marketCap":181339982},{"date":"2025-12-26","current":-3.40816,"twenty":-1.050981,"median":-0.545001,"eighty":-0.398837,"marketCap":130208053},{"date":"2026-01-02","current":-3.236974,"twenty":-1.111477,"median":-0.549157,"eighty":-0.39905,"marketCap":123667922},{"date":"2026-01-09","current":-2.451074,"twenty":-1.16928,"median":-0.552647,"eighty":-0.399948,"marketCap":93642777},{"date":"2026-01-16","current":-2.351299,"twenty":-1.182678,"median":-0.557977,"eighty":-0.400578,"marketCap":89830899},{"date":"2026-01-23","current":-2.578032,"twenty":-1.247239,"median":-0.558465,"eighty":-0.402359,"marketCap":98493164},{"date":"2026-01-30","current":-2.435274,"twenty":-1.269799,"median":-0.561956,"eighty":-0.404249,"marketCap":93039145},{"date":"2026-02-06","current":-2.662007,"twenty":-1.36824,"median":-0.565484,"eighty":-0.407726,"marketCap":101701410},{"date":"2026-02-13","current":-2.536044,"twenty":-1.420694,"median":-0.572344,"eighty":-0.408596,"marketCap":96889041},{"date":"2026-02-20","current":-2.536071,"twenty":-1.540898,"median":-0.574661,"eighty":-0.409242,"marketCap":96890059},{"date":"2026-02-27","current":-2.405345,"twenty":-1.831766,"median":-0.578189,"eighty":-0.409453,"marketCap":91895726},{"date":"2026-03-06","current":-2.492496,"twenty":-2.234293,"median":-0.579338,"eighty":-0.410856,"marketCap":95225281},{"date":"2026-03-13","current":-2.623221,"twenty":-2.344581,"median":-0.583582,"eighty":-0.413012,"marketCap":100219614},{"date":"2026-03-20","current":-2.638773,"twenty":-2.411331,"median":-0.585772,"eighty":-0.413742,"marketCap":90397426},{"date":"2026-03-27","current":-2.028037,"twenty":-2.43626,"median":-0.591133,"eighty":-0.413812,"marketCap":69475230},{"date":"2026-04-02","current":-2.076788,"twenty":-2.435274,"median":-0.593369,"eighty":-0.413812,"marketCap":71145307},{"date":"2026-04-10","current":-1.930536,"twenty":-2.417317,"median":-0.597275,"eighty":-0.414333,"marketCap":66135074},{"date":"2026-04-17","current":-1.521028,"twenty":-2.400116,"median":-0.605004,"eighty":-0.414681,"marketCap":52106422},{"date":"2026-04-24","current":-1.365025,"twenty":-2.394624,"median":-0.608494,"eighty":-0.414681,"marketCap":46762174},{"date":"2026-05-01","current":-1.394276,"twenty":-2.368094,"median":-0.611014,"eighty":-0.414686,"marketCap":47764220},{"date":"2026-05-08","current":-1.521028,"twenty":-2.346261,"median":-0.615922,"eighty":-0.415207,"marketCap":52106422},{"date":"2026-05-15","current":-1.930536,"twenty":-2.342443,"median":-0.621292,"eighty":-0.416072,"marketCap":66135074},{"date":"2026-05-22","current":-2.134847,"twenty":-2.337557,"median":-0.626653,"eighty":-0.416941,"marketCap":60456810},{"date":"2026-05-29","current":-1.969721,"twenty":-2.321068,"median":-0.62867,"eighty":-0.417289,"marketCap":55780593},{"date":"2026-06-05","current":-1.981516,"twenty":-2.281465,"median":-0.637581,"eighty":-0.417289,"marketCap":56114609},{"date":"2026-06-12","current":-1.851774,"twenty":-2.23843,"median":-0.653869,"eighty":-0.417289,"marketCap":52440438},{"date":"2026-06-18","current":-1.757416,"twenty":-2.210516,"median":-0.657312,"eighty":-0.417291,"marketCap":49768313},{"date":"2026-06-26","current":-1.757537,"twenty":-2.179667,"median":-0.663177,"eighty":-0.41747,"marketCap":49771738},{"date":"2026-07-02","current":-1.781287,"twenty":-2.170232,"median":-0.667831,"eighty":-0.418159,"marketCap":50444329},{"date":"2026-07-10","current":-1.67441,"twenty":-2.158437,"median":-0.69531,"eighty":-0.419028,"marketCap":47417669},{"date":"2026-07-17","current":-1.626909,"twenty":-2.134847,"median":-0.732985,"eighty":-0.419028,"marketCap":46072487},{"date":"2026-07-24","current":-1.828788,"twenty":-2.113794,"median":-0.753635,"eighty":-0.419028,"marketCap":51789511},{"date":"2026-07-31","current":-1.876289,"twenty":-2.111765,"median":-0.785584,"eighty":-0.419723,"marketCap":53134693},{"date":"2026-08-07","current":-2.078168,"twenty":-2.116169,"median":-0.805724,"eighty":-0.420245,"marketCap":58851717},{"date":"2026-08-14","current":-2.351299,"twenty":-2.160796,"median":-0.905302,"eighty":-0.42068,"marketCap":66586514},{"date":"2026-08-21","current":-2.197553,"twenty":-2.17317,"median":-0.936241,"eighty":-0.421462,"marketCap":79202648}],"updateTime":1787465677896},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DWTX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2660487065","title":"Dogwood Therapeutics to Host Virtual KOL Event on Halneuron for Chemotherapy-Induced Neuropathic Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487065","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487065?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:32","pubTimestamp":1786969964,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics to host virtual KOL event on Halneuron for chemotherapy-induced neuropathic painDogwood Therapeutics will host a virtual KOL event on Sept. 1, 2026 at 10:00 a.m. ET.Discussion to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL4wnfz9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","SG9999014021.USD","IE00B64PRP62.GBP","DWTX","LU2210149790.SGD","BK4112","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4139","NDAQ","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BKPKM429.USD","BCDF","SG9999014039.USD","SG9999014013.SGD","BK4588","LU2095319765.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659144391","title":"Analysts Offer Insights on Healthcare Companies: Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4D Molecular Therapeutics (FDMT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659144391","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659144391?lang=en_us&edition=fundamental","pubTime":"2026-08-14 21:00","pubTimestamp":1786712444,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Dogwood Therapeutics (DWTX), Talphera (TLPH) and 4...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dogwood-therapeutics-dwtx-talphera-tlph-and-4d-molecular-therapeutics-fdmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-dogwood-therapeutics-dwtx-talphera-tlph-and-4d-molecular-therapeutics-fdmt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","FDMT","BK4585","HCSG","BK4007","BK4588","DWTX","LU0029874061.USD","XBI","LU0128526141.USD","TLPH","BK4581","BK4137","BK4139","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659689141","title":"Dogwood Therapeutics Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659689141","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659689141?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:15","pubTimestamp":1786630502,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc reports results for the quarter ended June 30 - Earnings SummaryDogwood Therapeutics IncDWTX.OQreported a quarterly adjusted loss of 34 cents per share for the quarter ended J","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1I8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152843","title":"Dogwood Therapeutics Q2 FY26 Net Loss Widens to $11.5 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152843","media":"Reuters","labels":["dataReport","event","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152843?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:32","pubTimestamp":1786624324,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Q2 FY26 net loss widens to $11.5 millionDogwood Therapeutics posted a Q2 net loss attributable to common stockholders of $11.5 million, or $0.34 a share.R&D expense rose to $3.25 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDL67qHdb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,event,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","DWTX","BCDF","LU2095319765.USD","BK4588","IE00B64PRP62.GBP","SG9999014005.SGD","NDAQ","SG9999014021.USD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","SG9999014039.USD","LU0314104364.USD","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014013.SGD","BK4139","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659154059","title":"Dogwood Therapeutics Q2 EPS USD -0.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2659154059","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659154059?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624201,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLXF75WXS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659152838","title":"Press Release: Dogwood Therapeutics Announces Second Quarter 2026 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2659152838","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659152838?lang=en_us&edition=fundamental","pubTime":"2026-08-13 20:30","pubTimestamp":1786624200,"startTime":"0","endTime":"0","summary":"2b Chemotherapy Induced Neuropathic Pain  study, with top-line. results readout expected in the fall of 2026.-- SP16 granted IND approval from the FDA. Study to begin enrolling in the. second-half of 2026 for the treatment of chemotherapy induced pain and. peripheral neuropathy . The study is fully funded by the. National Cancer Institute and will be conducted at the University of. -- Dogwood commences Phase 2b long-term extension study to assess. Halneuron's reduction in pain over three months of treatment. Patients. completing the ongoing Halneuron 4-week CINP Phase 2b study are now. eligible to enroll in the new 12-week open-label follow-on trial.-- The Company appointed Iain Dukes, D.Phil., Venture Partner at OrbiMed, as. -- Cash on hand of $9.6 million provides operational runway through the. Phase 2b readout in the fourth quarter of 2026.Second Quarter 2026 Financial ResultsResearch and development expenses for the second quarter of 2026 were $3.2 million, compared to $2","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE000BZT7R73.USD","LU2265009873.SGD","VFH","LU0348723411.USD","LU1861217088.USD","R","XLF","LU2764263039.SGD","LU1400636491.USD","LU2125909593.SGD","LU0390134368.USD","LENZ","IE00B19Z8X17.USD","LATR","LU0345774391.USD","LU2404859741.USD","LU0868494708.USD","LU1037948541.HKD","LU1228905037.USD","IPAY","LU2089284900.SGD","TFNS","IE00B1XK9C88.USD","DWTX","LU0823434740.USD","UYG","FNCL","LU1236620750.USD","LU2023250504.SGD","LU1645745479.HKD","FDFF","LU1121112475.USD","LU1400636657.SGD","LU0029864427.USD","LU1814569148.SGD","LU1917777945.USD","LU1670756490.USD","IXG","LU0106261372.USD","LU1280957306.USD","TRUF","LU0158827781.USD","LU0689626769.HKD","IE0000B7K699.USD","LU1979441026.SGD","SG9999018865.SGD","IYG","LU0256863902.USD","V","LU2506952097.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657101696","title":"Dogwood Therapeutics Inc Expected to Post a Loss of 14 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2657101696","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657101696?lang=en_us&edition=fundamental","pubTime":"2026-08-07 19:10","pubTimestamp":1786101005,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics Inc <DWTX.OQ> expected to post a loss of14cents a share - Earnings PreviewDogwood Therapeutics IncDWTX.OQDWTX.Ois expected to  show no change in quarterly revenue when it reports  results on August 11  for the period ending June 30 2026LSEG's mean analyst estimate for Dogwood Therapeutics Inc is for a loss of 14 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $13.50, about 671.4% above its last closing price of $1.75This summary was machine generated August 7 at 11:10 GMT.  All figures in US dollars unless otherwise stated.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nL8N4440Y9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656525309","title":"Dogwood Therapeutics Posts Corporate Presentation on Non-Opioid Pain, Neuropathy Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2656525309","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656525309?lang=en_us&edition=fundamental","pubTime":"2026-08-04 03:44","pubTimestamp":1785786271,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipelineDogwood highlighted Halneuron injection, a tetrodotoxin-based Nav1.7 blocker, as its lead non-opioid progr","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nNDL3qHwVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652216524","title":"Dogwood Therapeutics Enrolls First 200 Patients in Phase 2b Neuropathic Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2652216524","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652216524?lang=en_us&edition=fundamental","pubTime":"2026-07-20 21:10","pubTimestamp":1784553032,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics (DWTX) said Monday it has enrolled the first 200 patients in its phase 2b trial evaluating its experimental therapy, Halneuron, for chemotherapy-induced neuropathic pain, keeping ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DWTX","BK4539","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652521530","title":"Dogwood enrolls first 200 patients in HAL-CINP trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2652521530","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652521530?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:35","pubTimestamp":1784550959,"startTime":"0","endTime":"0","summary":"Dogwood (DWTX) announced it has enrolled the first 200 patients in its ongoing HAL-CINP Phase 2b trial. HAL-CINP remains on track for top-line data...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/dogwood-enrolls-first-200-patients-in-hal-cinp-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/dogwood-enrolls-first-200-patients-in-hal-cinp-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IEZ","LU0256331488.USD","LU0306806265.USD","LU0306807586.USD","LU0321505439.SGD","LU0225284248.USD","LU0225771236.USD","LU0985481810.HKD","OIH","BK4139","BK4588","BK4585","LU0321505868.SGD","PXJ","BK4179","DWTX","HAL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213092","title":"Dogwood Therapeutics Announces Press Release Availability","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213092","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652213092?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:31","pubTimestamp":1784550676,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics announces press release availabilityDogwood Therapeutics enrolled the first 200 patients in its Halneuron Phase 2b HAL-CINP trial for chemotherapy-induced neuropathic pain.Top-lin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL6XvrN6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","LU2210149790.SGD","BK4112","BCDF","NDAQ","DWTX","BK4139","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652213728","title":"Dogwood Enrolls First 200 Patients in Ongoing Halneuron® Phase 2B Chemotherapy Induced Neuropathy Trial; Top-line Data Expected in Fall 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2652213728","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652213728?lang=en_us&edition=fundamental","pubTime":"2026-07-20 20:30","pubTimestamp":1784550600,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUA8VG70B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649649287","title":"Analysts Offer Insights on Healthcare Companies: Celcuity (CELC), Dogwood Therapeutics (DWTX) and Sanofi (OtherSNYNF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2649649287","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649649287?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:20","pubTimestamp":1783322406,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Celcuity (CELC), Dogwood Therapeutics (DWTX) and S...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-celcuity-celc-dogwood-therapeutics-dwtx-and-sanofi-othersnynf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-celcuity-celc-dogwood-therapeutics-dwtx-and-sanofi-othersnynf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","DWTX","BK4007","LU0029874061.USD","XBI","HCSG","XLV","BK4585","BK4581","SNYNF","BK4139","BK4137","LU0128526141.USD","BK4588","CELC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648659568","title":"Dogwood Therapeutics Posts Corporate Presentation on Non-opioid Pain, Neuropathy Drug Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2648659568","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648659568?lang=en_us&edition=fundamental","pubTime":"2026-07-01 08:37","pubTimestamp":1782866272,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipelineDogwood outlined key 2026 milestones for Halneuron injection in chemotherapy-induced neuropathic pain, inc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260701:nNDLbKDWXj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647955691","title":"Dogwood Therapeutics Names Orbimed’s Iain Dukes Chair of New Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647955691","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647955691?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:45","pubTimestamp":1782823529,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics names OrbiMed’s Iain Dukes chair of new scientific advisory boardDogwood Therapeutics named OrbiMed venture partner Iain Dukes chair of its newly formed Scientific Advisory Board.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL29F1v7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU1481600234.SGD","IE00BKPKM429.USD","SG9999014021.USD","IE00B64PRP62.GBP","LU1309081286.SGD","LU0575583348.USD","LU0203347892.USD","LU0985481810.HKD","BK4585","LU2210150020.SGD","LU1400636491.USD","SGXZ57979304.SGD","LU0225771236.USD","GSK.UK","LU0987226296.USD","LU0545562505.USD","BK4112","LU1481599808.USD","LU2210149790.SGD","LU1202635105.USD","SG9999001176.SGD","LU1400636657.SGD","IE00B3T34201.USD","LU0289739699.SGD","NDAQ","LU1046248800.SGD","DWTX","LU0058720904.USD","BK4139","IE00BWDBJ516.SGD","LU0161305163.EUR","LU0971552830.HKD","LU1228905037.USD","LU2468319806.SGD","SG9999014005.SGD","IE00BN0W2T93.GBP","IE00BQJZX424.USD","LU0211331839.USD","LU1064927863.SGD","LU1302929846.USD","LU0109981661.USD","LU2646069778.SGD","LU0203345920.USD","SG9999014013.SGD","LU1035777561.USD","LU1645745479.HKD","SG9999013999.USD","LU0225284248.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647556600","title":"Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at Orbimed, as Chair of Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2647556600","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647556600?lang=en_us&edition=fundamental","pubTime":"2026-06-30 20:45","pubTimestamp":1782823500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA4FNDR7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644243157","title":"Dogwood Therapeutics shareholders approve charter amendment increasing authorized shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2644243157","media":"Reuters","labels":["shareholding","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2644243157?lang=en_us&edition=fundamental","pubTime":"2026-06-18 04:56","pubTimestamp":1781729765,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics held its annual shareholder meeting on June 16, 2026.Shareholders backed an amendment to the certificate of incorporation to increase authorized common and preferred shares; the filing took effect June 17, 2026.Shareholders supported holding future advisory votes on executive pay on an annual basis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260617:nNDL71cthH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DWTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642929527","title":"Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2642929527","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642929527?lang=en_us&edition=fundamental","pubTime":"2026-06-12 21:43","pubTimestamp":1781271837,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics highlighted Halneuron injection for chemotherapy-induced neuropathic pain, targeting a Phase 2b data readout in fall 2026.Milestones include a Q4 2026 end-of-Phase 2 FDA submission for Halneuron in CINP.Phase 2b interim analysis set a 210-240 patient sample size to maintain 80%-85% power, citing an efficacy signal versus placebo.Pipeline update flagged SP16 IV in CIPPN with an FDA-accepted IND, with Phase 1b enrollment slated to start in Q3 2026.Corporate snapshot showed USD 13.2 million cash as of March 31, 2026 pro forma, with 33,629,553 shares outstanding.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dogwood Therapeutics Inc. published the original content used to generate this news brief on June 12, 2026, and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL7bB07z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636863485","title":"Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), MoonLake Immunotherapeutics (MLTX) and Dogwood Therapeutics (DWTX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636863485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636863485?lang=en_us&edition=fundamental","pubTime":"2026-05-20 00:50","pubTimestamp":1779209411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR), MoonLake Immunotherapeutics...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-vir-biotechnology-vir-moonlake-immunotherapeutics-mltx-and-dogwood-therapeutics-dwtx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4535","BK4137","VIR","LU0128526141.USD","MLTX","LU0029874061.USD","BK4588","BK4568","LABU","XLV","XBI","HCSG","BK4581","BK4139","DWTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636075180","title":"Dogwood Therapeutics launches 12-week Halneuron Phase 2b CINP extension trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2636075180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636075180?lang=en_us&edition=fundamental","pubTime":"2026-05-18 20:45","pubTimestamp":1779108317,"startTime":"0","endTime":"0","summary":"Dogwood Therapeutics launched a Phase 2b open-label extension study of Halneuron for chemotherapy-induced neuropathic pain, enrolling patients who complete its ongoing 4-week double-blind trial.Results from the extension study will be presented in the future, with the main 4-week trial still expected to deliver top-line results in fall 2026.The new 12-week follow-on trial aims to show whether pain relief can be sustained with longer treatment while expanding the safety profile, supporting an end-of-Phase 2 FDA package.An interim assessment from the ongoing study has already indicated a favorable treatment effect versus placebo, backing continued development and informing plans for a Phase 3 program targeted to start in the first half of 2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDLbjphsL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","DWTX","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4139","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":47,"code":"91000000","status":"200"}]}}